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LETTERS TO THE EDITOR 
Hemochron Versus HemoTec Activated 
Coagulation Time Target Values 
During Percutaneous Transluminal 
Coronary Angioplasty 
We read with great interest he results of a study by Avendano and 
Ferguson (1) dealing with the target activated clotting time values 
determined by two different clot detecting systems. We agree with the 
authors on the main results of this study that activated clotting time 
results achieved by different machines cannot be used interchangeably, 
and further prospective research is needed to determine the level of 
correct anticoagulation. 
The two systems use different clot detecting systems, which at least 
partly explains the finding that the HemTec system usually detects a
shorter activated clotting time. The HemTec system detects the early 
appearance of the fibrin mesh, whereas the Hemochron system detects 
the time required for the formation of a firm clot capable of grabbing 
the magnet in a test tube and, hence, stops the timer. 
Our main criticism concerns the statistical method used in this 
study. Linear regression analysis is not an appropriate statistical test 
for comparing two methods measuring the same clinical variable. The 
correlation coefficient isa measure of the strength of linear association 
between two variables and does not show the level of agreement and 
contributes no information as to whether the two methods can be used 
interchangeably. The correlation coefficient also depends on the ran- 
dom measurement error and the range of measurements (2). One of 
the correct statistical tests for comparison of methods was published by 
Altman and Bland in 1983 (2). They suggested a simple calculation of 
the difference between the results achieved by the two methods and 
plotted this against heir mean value. The mean difference is the bias 
and the mean difference +2 SD is the limit of agreement. If this limit 
of agreement is smaller than the difference with clinical significance, 
then the two methods can be used interchangeably. The interpretation 
of the limit of agreement must depend on the clinical circumstances, 
and it is not possible to use statistics to define acceptable agreement. 
This statistical test has widely been used for comparison of methods 
studies (3-5). 
Statistical techniques provide the tools for assessing the validity of 
a finding. Use of the appropriate statistical method facilitates the 
correct interpretation of the results. It is a pity that >10 years after 
publication of an easy, clinically oriented statistical method, studies 
using incorrect statistical methods are still appearing in journals of 
international reputation. 
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Reply 
We appreciate the insightful comments of Varga et al. regarding the 
appropriate statistical techniques for comparing two different mea- 
surements of the same clinical variable. In response to their query, we 
have included an analysis of our data (1) using the technique published 
by Altman and Bland (2) (Fig. 1). This graph shows the difference 
between the two measurements plotted as a function of the mean of 
the two measurements. This type of analysis hows the variability of the 
two measurements over the entire range of application and is primarily 
useful for indicating whether one type of measurement can be used 
interchangeably with another. As is obvious from Figure 1 (and as 
stated in our original article), the Hemochron activated clotting time 
measurements tend to exceed HemoTec activated clotting time mea- 
surements; the degree of variability increases markedly after the 
administration f heparin. The implications are exactly the same as in 
the original article: Hemochron and HemoTec activated clotting time 
measurements cannot be used interchangeably. The regression equa- 
tion mentioned in the article was intended only to illustrate that a 
relation existed and should not be used as a basis to "predict" one 
activated clotting time measurement on the basis of measurements 
using the other technique. We agree that prospective data for both 
Figure 1. Difference between Hemochron and HemoTec measure- 
ments plotted as a function of the mean value of the two measure- 
ments. The degree of variability increases in the higher range of 
measurements, after the administration of heparin. 
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